1. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
- Author
-
Deniz H, Kibar Y, Güldür ME, and Bakir K
- Subjects
- Adenocarcinoma metabolism, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Biomarkers, Tumor metabolism, Chi-Square Distribution, Diagnosis, Differential, Female, Humans, Immunohistochemistry, Lung Neoplasms metabolism, Male, Mesothelioma metabolism, Middle Aged, Pleura metabolism, Pleural Neoplasms diagnosis, Pleural Neoplasms metabolism, Solitary Fibrous Tumor, Pleural metabolism, Adenocarcinoma diagnosis, Antibodies, Monoclonal metabolism, Lung metabolism, Lung Neoplasms diagnosis, Mesothelioma diagnosis, Solitary Fibrous Tumor, Pleural diagnosis
- Abstract
Since pulmonary adenocarcinomas, malignant mesotheliomas (MM), and sometimes benign mesothelial proliferations show a great histomorphological resemblance to each other, an immunohistochemical panel is usually necessary for differential diagnosis. D2-40 is an available monoclonal antibody, which is already in use as a lymphatic endothelial marker. It has also been suggested to be useful in identifying the mesothelial differentiation. The aim of this study is to compare D2-40 immunostaining in MM, pulmonary adenocarcinoma, and benign mesothelial proliferations. In this retrospective study, D2-40 immunostaining was investigated in 37 cases of MM, 36 cases of pulmonary adenocarcinoma, and 31 cases of benign mesothelial proliferation. The diagnosis of MM had previously been confirmed by a panel including calretinin, CK5/6, and CEA. Predominantly membranous immunoreactivity was observed in 51% of MMs and in 55% of benign mesothelial proliferations. All the 36 pulmonary adenocarcinomas were negative. These results were statistically significant (p<0.001). We believe that D2-40 may be helpful in the differential diagnosis of MM from pleural involvement of pulmonary adenocarcinoma.
- Published
- 2009
- Full Text
- View/download PDF